Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
LUCD

LUCD - Lucid Diagnostics Inc. Stock Price, Fair Value and News

$1.15-0.07 (-5.74%)
Market Closed

15/100

LUCD

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

15/100

LUCD

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$0.97

Target 3M

$1.09

Target 6M

$1.03

LUCD Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

LUCD Price Action

Last 7 days

1.8%

Last 30 days

7.5%

Last 90 days

-4.2%

Trailing 12 Months

27.8%

LUCD RSI Chart

LUCD Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

LUCD Valuation

Market Cap

150.6M

Price/Earnings (Trailing)

-2.83

Price/Sales (Trailing)

34.03

EV/EBITDA

-1.97

Price/Free Cashflow

-3.44

LUCD Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$0.97

Target 3M

$1.09

Target 6M

$1.03

LUCD Fundamentals

LUCD Revenue

Revenue (TTM)

4.4M

Rev. Growth (Yr)

2.39%

LUCD Earnings

Earnings (TTM)

-53.3M

Earnings Growth (Yr)

15.96%

Earnings Growth (Qtr)

-134.22%

LUCD Profitability

Operating Margin

86.72%

EBT Margin

-1204.18%

Return on Equity

-206.25%

Return on Assets

-100.16%

Free Cashflow Yield

-29.05%

LUCD Investor Care

Shares Dilution (1Y)

159.90%

Diluted EPS (TTM)

-0.87

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20254.2M4.4M4.4M0
20243.0M3.8M4.2M4.3M
2023634.0K793.0K1.5M2.4M
2022533.0K481.0K429.0K377.0K
2021000585.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Lucid Diagnostics Inc.

LUCD
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma (EAC). It offers EsoCheck, a cell collection device to prevent EAC deaths; and EsoGuard, an Esophageal DNA Test. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
0
 CEO
 WEBSITEluciddx.com
 SECTORHealthcare
 INDUSTRYMedical Devices

Lucid Diagnostics Inc. Frequently Asked Questions

LUCD is the stock ticker symbol of Lucid Diagnostics Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Lucid Diagnostics Inc. is 150.56 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check LUCD's fair value in chart for subscribers.

The fair value guage provides a quick view whether LUCD is over valued or under valued. Whether Lucid Diagnostics Inc. is cheap or expensive depends on the assumptions which impact Lucid Diagnostics Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LUCD.

As of Wed Jan 28 2026, LUCD's PE ratio (Price to Earnings) is -2.83 and Price to Sales (PS) ratio is 34.03. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LUCD PE ratio will change depending on the future growth rate expectations of investors.